16 results on '"Chishala Chishala"'
Search Results
2. Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases
- Author
-
Salie, M. Taariq, Yang, Jing, Ramírez Medina, Carlos R., Zühlke, Liesl J., Chishala, Chishala, Ntsekhe, Mpiko, Gitura, Bernard, Ogendo, Stephen, Okello, Emmy, Lwabi, Peter, Musuku, John, Mtaja, Agnes, Hugo-Hamman, Christopher, El-Sayed, Ahmed, Damasceno, Albertino, Mocumbi, Ana, Bode-Thomas, Fidelia, Yilgwan, Christopher, Amusa, Ganiyu A., Nkereuwem, Esin, Shaboodien, Gasnat, Da Silva, Rachael, Lee, Dave Chi Hoo, Frain, Simon, Geifman, Nophar, Whetton, Anthony D., Keavney, Bernard, and Engel, Mark E.
- Published
- 2022
- Full Text
- View/download PDF
3. Regional Patterns and Association Between Obesity and Hypertension in Africa: Evidence From the H3Africa CHAIR Study
- Author
-
Akpa, Onoja M., Made, Felix, Ojo, Akinlolu, Ovbiagele, Bruce, Adu, Dwomoa, Motala, Ayesha A., Mayosi, Bongani M., Adebamowo, Sally N., Engel, Mark E., Tayo, Bamidele, Rotimi, Charles, Salako, Babatunde, Akinyemi, Rufus, Gebregziabher, Mulugeta, Sarfo, Fred, Wahab, Kolawole, Agongo, Godfred, Alberts, Marianne, Ali, Stuart A., Asiki, Gershim, Boua, Romuald P., Gómez-Olivé, F. Xavier, Mashinya, Felistas, Micklesfield, Lisa, Mohamed, Shukri F., Nonterah, Engelbert A., Norris, Shane A., Sorgho, Hermann, Tollman, Stephen, Parekh, Rulan S., Chishala, Chishala, Ekoru, Kenneth, Waddy, Salina P., Peprah, Emmanuel, Mensah, George A., Wiley, Ken, Troyer, Jennifer, Ramsay, Michèle, and Owolabi, Mayowa O.
- Published
- 2020
- Full Text
- View/download PDF
4. Rationale, Design, and the Baseline Characteristics of the RHDGen (The Genetics of Rheumatic Heart Disease) Network Study†
- Author
-
Machipisa, Tafadzwa, primary, Chishala, Chishala, additional, Shaboodien, Gasnat, additional, Zühlke, Liesl J., additional, Muhamed, Babu, additional, Pandie, Shahiemah, additional, Vries, Jantina de, additional, Laing, Nakita, additional, Joachim, Alexia, additional, Daniels, Rezeen, additional, Ntsekhe, Mpiko, additional, Hugo-Hamman, Christopher T., additional, Gitura, Bernard, additional, Ogendo, Stephen, additional, Lwabi, Peter, additional, Okello, Emmy, additional, Damasceno, Albertino, additional, Novela, Celia, additional, Mocumbi, Ana O., additional, Madeira, Geoffrey, additional, Musuku, John, additional, Mtaja, Agnes, additional, ElSayed, Ahmed, additional, Alhassan, Huda H.M., additional, Bode-Thomas, Fidelia, additional, Yilgwan, Christopher, additional, Amusa, Ganiyu, additional, Nkereuwem, Esin, additional, Mulder, Nicola, additional, Ramesar, Raj, additional, Lesosky, Maia, additional, Cordell, Heather J., additional, Chong, Michael, additional, Keavney, Bernard, additional, Paré, Guillaume, additional, Engel, Mark E., additional, Mayosi, Bongani M, additional, Mayosi, B M, additional, El Sayed, A, additional, Mondo, C, additional, Ogah, O, additional, Cupido, B, additional, Pepeta, L, additional, Auala, T, additional, Brinkman, C, additional, Sikwaya, L, additional, Omulo, Tom, additional, Fabula, A, additional, Abdelhalim, A, additional, Alhajapo, H, additional, Idris, E, additional, Salih, S, additional, Okeahialam, B, additional, Danbauchi, S, additional, Ige, O, additional, de Vries, J, additional, Francis, V, additional, Gili, F., additional, Kraba, P, additional, Vergotine, R., additional, Kamuli, S, additional, Pearce, L, additional, Saaiman, J, additional, Faure, M, additional, Masiye, F, additional, Matshabane, O P, additional, Munung, N S, additional, Ditta, R, additional, Hodge, A, additional, Awases, A, additional, Bock, A, additional, Nzuza, S, additional, Mangami, C, additional, Amanyanga, H, additional, Mneumbo, A, additional, Kitoleko, S, additional, Kebba, J, additional, Machava, M, additional, Govo, V, additional, Marcaulay, OA, additional, Badung, D, additional, and Durojaiye-Amodu, C, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
- Author
-
Derek M. Yellon, Motasim Badri, Mergan Naidoo, Omaima Abozaid, Brian Kiggundu, Eltayeb Hamid, Trevor Gould, Chishala Chishala, Isam Gaafar, Ebrahim Variava, Makoali Makotoko, Waldo Welgemoed, Ehab Ali Elmakki, Derek J. Hausenloy, Arthur Mutyaba, Paul Xafis, Sara Giesz, Abdullah Bajaber, Malcolm Walker, Keiran Mwazo, Kishal Lukhna, Abdelbagi Sidahmed Ali, Elijah Ogola, Nasief van der Schyff, Mpiko Ntsekhe, Awad Mohamed, Mohamed Elhadi Abdelhameed, Alistair Calver, and Emmy Okello
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Trial Designs ,Cardioprotection ,Chest pain ,Reperfusion therapy ,hemic and lymphatic diseases ,medicine ,Pharmacology (medical) ,Myocardial infarction ,Pharmacology ,business.industry ,Hospitalization for heart failure ,Percutaneous coronary intervention ,General Medicine ,Thrombolysis ,medicine.disease ,Clinical trial ,ST elevation myocardial infarction ,Blood pressure ,Heart failure ,Emergency medicine ,Remote ischaemic conditioning ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Ischaemia/reperfusion injury - Abstract
Purpose Despite evidence of myocardial infarct size reduction in animal studies, remote ischaemic conditioning (RIC) failed to improve clinical outcomes in the large CONDI-2/ERIC-PPCI trial. Potential reasons include that the predominantly low-risk study participants all received timely optimal reperfusion therapy by primary percutaneous coronary intervention (PPCI). Whether RIC can improve clinical outcomes in higher-risk STEMI patients in environments with poor access to early reperfusion or PPCI will be investigated in the RIC-AFRICA trial. Methods The RIC-AFRICA study is a sub-Saharan African multi-centre, randomized, double-blind, sham-controlled clinical trial designed to test the impact of RIC on the composite endpoint of 30-day mortality and heart failure in 1200 adult STEMI patients without access to PPCI. Randomized participants will be stratified by whether or not they receive thrombolytic therapy within 12 h or arrive outside the thrombolytic window (12–24 h). Participants will receive either RIC (four 5-min cycles of inflation [20 mmHg above systolic blood pressure] and deflation of an automated blood pressure cuff placed on the upper arm) or sham control (similar protocol but with low-pressure inflation of 20 mmHg and deflation) within 1 h of thrombolysis and applied daily for the next 2 days. STEMI patients arriving greater than 24 h after chest pain but within 72 h will be recruited to participate in a concurrently running independent observational arm. Conclusion The RIC-AFRICA trial will determine whether RIC can reduce rates of death and heart failure in higher-risk sub-optimally reperfused STEMI patients, thereby providing a low-cost, non-invasive therapy for improving health outcomes.
- Published
- 2021
6. Rationale, Design, and the Baseline Characteristics of the RHDGen (The Genetics of Rheumatic Heart Disease) Network Study†
- Author
-
Tafadzwa, Machipisa, Chishala, Chishala, Gasnat, Shaboodien, Liesl J, Zühlke, Babu, Muhamed, Shahiemah, Pandie, Jantina de, Vries, Nakita, Laing, Alexia, Joachim, Rezeen, Daniels, Mpiko, Ntsekhe, Christopher T, Hugo-Hamman, Bernard, Gitura, Stephen, Ogendo, Peter, Lwabi, Emmy, Okello, Albertino, Damasceno, Celia, Novela, Ana O, Mocumbi, Geoffrey, Madeira, John, Musuku, Agnes, Mtaja, Ahmed, ElSayed, Huda H M, Alhassan, Fidelia, Bode-Thomas, Christopher, Yilgwan, Ganiyu, Amusa, Esin, Nkereuwem, Nicola, Mulder, Raj, Ramesar, Maia, Lesosky, Heather J, Cordell, Michael, Chong, Bernard, Keavney, Guillaume, Paré, Mark E, Engel, and C, Durojaiye-Amodu
- Subjects
General Medicine - Abstract
Background: The genetics of rheumatic heart disease (RHDGen) Network was developed to assist the discovery and validation of genetic variations and biomarkers of risk for rheumatic heart disease (RHD) in continental Africans, as a part of the global fight to control and eradicate rheumatic fever/RHD. Thus, we describe the rationale and design of the RHDGen study, comprising participants from 8 African countries. Methods: RHDGen screened potential participants using echocardiography, thereafter enrolling RHD cases and ethnically-matched controls for whom case characteristics were documented. Biological samples were collected for conducting genetic analyses, including a discovery case-control genome-wide association study (GWAS) and a replication trio family study. Additional biological samples were also collected, and processed, for the measurement of biomarker analytes and the biomarker analyses are underway. Results: Participants were enrolled into RHDGen between December 2012 and March 2018. For GWAS, 2548 RHD cases and 2261 controls (3301 women [69%]; mean age [SD], 37 [16.3] years) were available. RHD cases were predominantly Black (66%), Admixed (24%), and other ethnicities (10%). Among RHD cases, 34% were asymptomatic, 26% had prior valve surgery, and 23% had atrial fibrillation. The trio family replication arm included 116 RHD trio probands and 232 parents. Conclusions: RHDGen presents a rare opportunity to identify relevant patterns of genetic factors and biomarkers in Africans that may be associated with differential RHD risk. Furthermore, the RHDGen Network provides a platform for further work on fully elucidating the causes and mechanisms associated with RHD susceptibility and development.
- Published
- 2022
7. Regional Patterns and Association Between Obesity and Hypertension in Africa
- Author
-
Akinlolu Ojo, Rulan S. Parekh, Shane A. Norris, Engelbert A. Nonterah, George A. Mensah, Marianne Alberts, Romuald P. Boua, Sally N. Adebamowo, Bamidele O. Tayo, Rufus Akinyemi, Shukri F. Mohamed, Bruce Ovbiagele, Chishala Chishala, Gershim Asiki, Godfred Agongo, Lisa K. Micklesfield, Stephen Tollman, F. Xavier Gómez-Olivé, Felistas Mashinya, Mayowa O. Owolabi, Ayesha A. Motala, Michèle Ramsay, Dwomoa Adu, Jennifer L. Troyer, Kolawole Wahab, Charles N. Rotimi, Onoja Akpa, Hermann Sorgho, Kenneth Ekoru, Bongani M. Mayosi, Felix Made, Salina P. Waddy, Mulugeta Gebregziabher, Stuart A. Ali, Fred Stephen Sarfo, Babatunde L. Salako, Emmanuel Peprah, Mark E Engel, and Ken Wiley
- Subjects
education.field_of_study ,Younger age ,business.industry ,Population ,Mean age ,Odds ratio ,030204 cardiovascular system & hematology ,medicine.disease ,Obesity ,Odds ,03 medical and health sciences ,0302 clinical medicine ,Blood pressure ,Internal Medicine ,medicine ,030212 general & internal medicine ,education ,business ,Generalized estimating equation ,Demography - Abstract
Hypertension and obesity are the most important modifiable risk factors for cardiovascular diseases, but their association is not well characterized in Africa. We investigated regional patterns and association of obesity with hypertension among 30 044 continental Africans. We harmonized data on hypertension (defined as previous diagnosis/use of antihypertensive drugs or blood pressure [BP]≥140/90 mmHg/BP≥130/80 mmHg) and obesity from 30 044 individuals in the Cardiovascular H3Africa Innovation Resource across 13 African countries. We analyzed data from population-based controls and the Entire Harmonized Dataset. Age-adjusted and crude proportions of hypertension were compared regionally, across sex, and between hypertension definitions. Logit generalized estimating equation was used to determine the independent association of obesity with hypertension ( P value
- Published
- 2020
8. Additional file 1 of Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases
- Author
-
Salie, M. Taariq, Yang, Jing, Ram��rez Medina, Carlos R., Z��hlke, Liesl J., Chishala, Chishala, Ntsekhe, Mpiko, Gitura, Bernard, Ogendo, Stephen, Okello, Emmy, Lwabi, Peter, Musuku, John, Mtaja, Agnes, Hugo-Hamman, Christopher, El-Sayed, Ahmed, Damasceno, Albertino, Mocumbi, Ana, Bode-Thomas, Fidelia, Yilgwan, Christopher, Amusa, Ganiyu A., Nkereuwem, Esin, Shaboodien, Gasnat, Da Silva, Rachael, Lee, Dave Chi Hoo, Frain, Simon, Geifman, Nophar, Whetton, Anthony D., Keavney, Bernard, and Engel, Mark E.
- Abstract
Additional file 1: Figure S1. Scatter plots of BMI and age in cases and controls with their density plots in each group. Figure S2. Percentage of missing data in proteins with dashed red line representing the cutoff line. Figure S3. Pearson correlation coefficients of protein expression with BMI/Age among case and control samples. Correlation coefficients are in general weak, and not systematically different between cases and controls. Figure S4. Errorbar plots of protein expressions in females (x-axis) and males (y-axis) in case and control samples, respectively. The dashed lines are identity lines. Table S1. The eight African countries contributing participants in the study. Table S2. Mean of log2-scaled protein expression quantities in cases and controls, log2 foldchange between cases and controls, p-values from student t-test and adjusted p-values for multiple comparisons (only proteins with adjusted p value
- Published
- 2022
- Full Text
- View/download PDF
9. Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
- Author
-
Lukhna, Kishal, primary, Hausenloy, Derek J., additional, Ali, Abdelbagi Sidahmed, additional, Bajaber, Abdullah, additional, Calver, Alistair, additional, Mutyaba, Arthur, additional, Mohamed, Awad Abdalla, additional, Kiggundu, Brian, additional, Chishala, Chishala, additional, Variava, Ebrahim, additional, Elmakki, Ehab Ali, additional, Ogola, Elijah, additional, Hamid, Eltayeb, additional, Okello, Emmy, additional, Gaafar, Isam, additional, Mwazo, Keiran, additional, Makotoko, Makoali, additional, Naidoo, Mergan, additional, Abdelhameed, Mohamed Elhadi, additional, Badri, Motasim, additional, van der Schyff, Nasief, additional, Abozaid, Omaima, additional, Xafis, Paul, additional, Giesz, Sara, additional, Gould, Trevor, additional, Welgemoed, Waldo, additional, Walker, Malcolm, additional, Ntsekhe, Mpiko, additional, and Yellon, Derek M, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals
- Author
-
Machipisa, Tafadzwa, primary, Chong, Michael, additional, Muhamed, Babu, additional, Chishala, Chishala, additional, Shaboodien, Gasnat, additional, Pandie, Shahiemah, additional, de Vries, Jantina, additional, Laing, Nakita, additional, Joachim, Alexia, additional, Daniels, Rezeen, additional, Ntsekhe, Mpiko, additional, Hugo-Hamman, Christopher T., additional, Gitura, Bernard, additional, Ogendo, Stephen, additional, Lwabi, Peter, additional, Okello, Emmy, additional, Damasceno, Albertino, additional, Novela, Celia, additional, Mocumbi, Ana O., additional, Madeira, Goeffrey, additional, Musuku, John, additional, Mtaja, Agnes, additional, ElSayed, Ahmed, additional, Elhassan, Huda H. M., additional, Bode-Thomas, Fidelia, additional, Okeahialam, Basil N., additional, Zühlke, Liesl J., additional, Mulder, Nicola, additional, Ramesar, Raj, additional, Lesosky, Maia, additional, Parks, Tom, additional, Cordell, Heather J., additional, Keavney, Bernard, additional, Engel, Mark E., additional, and Paré, Guillaume, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals
- Author
-
Babu Muhamed, Agnes Mtaja, Tom Parks, Shahiemah Pandie, Huda H.M. Elhassan, Mark E Engel, Goeffrey Madeira, Emmy Okello, Michael Chong, Ahmed Elsayed, Guillaume Paré, Bernard Keavney, Tafadzwa Machipisa, Ana Olga Mocumbi, Nakita Laing, Nicola Mulder, John Musuku, Liesl Zühlke, Célia Novela, Maia Lesosky, Jantina de Vries, Alexia Joachim, Gasnat Shaboodien, Chishala Chishala, Raj Ramesar, Fidelia Bode-Thomas, Bernard Gitura, Albertino Damasceno, Stephen Ogendo, Mpiko Ntsekhe, Basil N Okeahialam, Peter Lwabi, Rezeen Daniels, Christopher Hugo-Hamman, and Heather J. Cordell
- Subjects
Male ,Proband ,Multifactorial Inheritance ,Cardiac & Cardiovascular Systems ,Health Status ,Genome-wide association study ,030204 cardiovascular system & hematology ,Cardiovascular System ,MIXED-MODEL ,0302 clinical medicine ,GWAS ,030212 general & internal medicine ,Child ,Original Investigation ,RISK ,Incidence ,Blacks ,Middle Aged ,Echocardiography ,Disease Progression ,Pacific islanders ,Rheumatic fever ,Female ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,Adult ,GENETICS ,Adolescent ,Genotype ,Black People ,Locus (genetics) ,Polymorphism, Single Nucleotide ,Young Adult ,03 medical and health sciences ,FEVER ,Genetic predisposition ,medicine ,Humans ,Genetic Predisposition to Disease ,INCOME COUNTRIES ,GENOME-WIDE ASSOCIATION ,COMMON ,Retrospective Studies ,Science & Technology ,business.industry ,Rheumatic Heart Disease ,Odds ratio ,Heritability ,medicine.disease ,REGISTRY ,Africa ,Cardiovascular System & Cardiology ,business ,Follow-Up Studies ,Genome-Wide Association Study ,Demography - Abstract
IMPORTANCE: Rheumatic heart disease (RHD), a sequela of rheumatic fever characterized by permanent heart valve damage, is the leading cause of cardiac surgery in Africa. However, its pathophysiologic characteristics and genetics are poorly understood. Understanding genetic susceptibility may aid in prevention, control, and interventions to eliminate RHD. OBJECTIVE: To identify common genetic loci associated with RHD susceptibility in Black African individuals. DESIGN, SETTING, AND PARTICIPANTS: This multicenter case-control genome-wide association study (GWAS), the Genetics of Rheumatic Heart Disease, examined more than 7 million genotyped and imputed single-nucleotide variations. The 4809 GWAS participants and 116 independent trio families were enrolled from 8 African countries between December 31, 2012, and March 31, 2018. All GWAS participants and trio probands were screened by use of echocardiography. Data analyses took place from May 15, 2017, until March 14, 2021. MAIN OUTCOMES AND MEASURES: Genetic associations with RHD. RESULTS: This study included 4809 African participants (2548 RHD cases and 2261 controls; 3301 women [69%]; mean [SD] age, 36.5 [16.3] years). The GWAS identified a single RHD risk locus, 11q24.1 (rs1219406 [odds ratio, 1.65; 95% CI, 1.48-1.82; P = 4.36 × 10(−8)]), which reached genome-wide significance in Black African individuals. Our meta-analysis of Black (n = 3179) and admixed (n = 1055) African individuals revealed several suggestive loci. The study also replicated a previously reported association in Pacific Islander individuals (rs11846409) at the immunoglobulin heavy chain locus, in the meta-analysis of Black and admixed African individuals (odds ratio, 1.16; 95% CI, 1.06-1.27; P = 1.19 × 10(−3)). The HLA (rs9272622) associations reported in Aboriginal Australian individuals could not be replicated. In support of the known polygenic architecture for RHD, overtransmission of a polygenic risk score from unaffected parents to affected probands was observed (polygenic transmission disequilibrium testing mean [SE], 0.27 [0.16] SDs; P = .04996), and the chip-based heritability was estimated to be high at 0.49 (SE = 0.12; P = 3.28 × 10(−5)) in Black African individuals. CONCLUSIONS AND RELEVANCE: This study revealed a novel candidate susceptibility locus exclusive to Black African individuals and an important heritable component to RHD susceptibility in African individuals.
- Published
- 2021
12. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE) : an international, randomised, placebo-controlled trial
- Author
-
P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, Purnima Rao-Melacini, Andreas Hoeft, Salim Yusuf, P.J. Devereaux, Shrikant I. Bangdiwala, Stuart Connolly, John Eikelboom, Janice Pogue, Daniel I. Sessler, Sara Di Diodato, Zora Gasic, Louise J. Mastrangelo, Sarah H. Molnar, Jennifer L. Swanson, Makayla L. Tosh, Jennifer R. Wells, Rafael Diaz, Clara K. Chow, Beatriz Gonzales, Skarlet Vásquez, Petr Jansky, Radovan Dušek, Christian S. Meyhoff, Pierre Coriat, Maria Wittmann, Gerald Yonga, Nandini Mathur, Elena Seletti, German Malaga, Bernadette A. Tumanan-Mendoza, Maria Pamela A. Tagle, Bruce M. Biccard, Pablo Alonso-Coello, Ekaterine Popova, Martin Shields, Yannick Le Manach, Paul Moayyedi, Sander van Zanten, Edith Fleischmann, Amit Garg, Kamilu Karaye, Edward McFalls, Alben Sigamani, Emilie Belley-Côté, Grzegorz Biedroń, Flavia Borges, Steffan Frosi Stella, Christian Haarmark Nielsen, Darryl P. Leong, Jessica Spence, Allen Tran, Katarzyna Wawrzycka-Adamczyk, Stephen S. Yang, Terence Yung, D. George Wyse, Davy Cheng, David E. Johnstone, George A. Wells, Philip Joseph, Ameen Patel, Krysten Gregus, Kelly Lawrence, Lindsay Doharris, David Conen, Jason Cheung, Jim Douketis, Douglas Wright, Spencer Wikkerink, William Dechert, Mohamed Panju, Khalid Azzam, Theodore Rapanos, Tomas Van Helder, Anjali Shroff, Jacqueline Hare, Biniam Kidane, Thang Nguyen, Larissa Leydier, Vanessa Bayaraa, Joel Parlow, Deborah A. DuMerton, Amar Thakrar, Jessica Shelley, Benoit Deligne, Roberta Daila Carling, Marko Mrkobrada, George K. Dresser, Michael J. Jacka, David Hornstein, Gerrit B. Winkelaar, Zoeb Hussain Haider, Pravina Prashant Lanjewar, Valsamma Varughese, Rajneesh Calton, Hemani Ahuja, Preetha George, Ambika Sharma, Keyur Sureshchandra Bhatt, Dhaval Odhavajibhai Mangukiya, Karshan Vira Nandaniya, Viral Vasantrai Parekh, Ashok Bhaskaran Pillai, Vidya P. Menon, Sanjay Channappa Desai, Ravinder Singh Sidhu, Sandeep Kumar Gupta, Robbie K. George, T.R. Gurunath, Leanne W. Drummond, Alexandra M. Torborg, Belinda S. Küsel, Prebashini Naidoo, Datshana P. Naidoo, Chantal Rajah, Zane Farina, Richard Peter von Rahden, Simphiwe Gumede, Chishala Chishala, Ettienne Coetzee, Robert A. Dyer, Johan Diedericks, Piotr Bielański, Bogusz Kaczmarek, Dorota Studzińska, Maciej Zaniewski, Marek Józef Libura, Tomasz Mikołaj Zacharias-Nalichowski, Aurelia A.S. Sega, Jakub Salwa, Mateusz Kózka, Jacek Górka, Anna Wludarczyk, Ilona Nowak-Kózka, Paweł Szczepan Grudzień, Jaroslaw W. Gucwa, Michał Piotr Słowiaczek, Paweł P.D. Dobosz, Ismail Gögenur, Jens Ravn Eriksen, Tine Borup, Tove Kirkegaard, Dan Isbye, Asger Sonne, Lars S. Rasmussen, Sofie Pedersen, Hannibal Troensegaard, Camilla L. Duus, Benedikte M. Halle, Ossian N. Gundel, Katrine F. Bernholm, Kristian Rønsholt Martinsen, Søren Pedersen, Theis S. Itenov, Elena Camio, Carles Vázquez, Silvia Matarin, Esther Cano, Jesús Álvarez-García, Inmaculada India, Aránzazu González-Osuna, Marc Vives, Elena Rosselló, Ana B. Serrano, Maurizio Turiel, Lorenzo Drago, Chiara Colombo, Federica Marra, Lucio Mos, Franco Arteni, Rosalba Lembo, Alessandro Ortalda, Simonetta Passarani, Zhirajr Mokini, Estevao Lanna Figueiredo, Gustavo Fonseca Werner, Joao Luiz Petriz, Lilia Nigro Maia, Ricardo R. Bergo, Dalton Bertolim Precoma, José Francisco Kerr Saraiva, Oscar Gomez Vilamajo, Eduardo Allegrini, Mariano Benzadón, Maria Leonor Parody, Ernesto A. Duronto, Adrián C. Ingaramo, Gustavo Adolfo Parra, Danny Novoa, Scott A. Miller, Sabu Thomas, Sudhakar P. Karlapudi, Mohamad H. Bourji, Subhash Banerjee, Anita Gupta, Isaac O. Opole, Michal Fischer, Victor Lecaros Mendoza, Eugenio Borja Reyes, Richard J. Pierson, Martin O. Shields, Vincent Piriou, Kai Zacharowski, Aida Rotta-Rotta, Main Paper, Sadeesh K. Srinathan, Prashant Rahate, Navneet Chaudhry, Bogani Mayosi, and Mike Sharma
- Subjects
Male ,medicine.medical_specialty ,Myocardial Infarction ,Placebo-controlled study ,Hemorrhage ,030204 cardiovascular system & hematology ,Placebo ,Antithrombins ,Dabigatran ,law.invention ,Peripheral Arterial Disease ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,030202 anesthesiology ,law ,Internal medicine ,medicine ,Humans ,Perioperative Period ,Stroke ,Aged ,Aged, 80 and over ,business.industry ,Hazard ratio ,Proton Pump Inhibitors ,Thrombosis ,Venous Thromboembolism ,General Medicine ,Perioperative ,Placebo Effect ,medicine.disease ,Troponin ,Clinical trial ,Treatment Outcome ,Female ,business ,Omeprazole ,medicine.drug - Abstract
Summary Background Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent a broader range of vascular complications in patients with MINS is unknown. The MANAGE trial assessed the potential of dabigatran to prevent major vascular complications among such patients. Methods In this international, randomised, placebo-controlled trial, we recruited patients from 84 hospitals in 19 countries. Eligible patients were aged at least 45 years, had undergone non-cardiac surgery, and were within 35 days of MINS. Patients were randomly assigned (1:1) to receive dabigatran 110 mg orally twice daily or matched placebo for a maximum of 2 years or until termination of the trial and, using a partial 2-by-2 factorial design, patients not taking a proton-pump inhibitor were also randomly assigned (1:1) to omeprazole 20 mg once daily, for which results will be reported elsewhere, or matched placebo to measure its effect on major upper gastrointestinal complications. Research personnel randomised patients through a central 24 h computerised randomisation system using block randomisation, stratified by centre. Patients, health-care providers, data collectors, and outcome adjudicators were masked to treatment allocation. The primary efficacy outcome was the occurrence of a major vascular complication, a composite of vascular mortality and non-fatal myocardial infarction, non-haemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism. The primary safety outcome was a composite of life-threatening, major, and critical organ bleeding. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01661101. Findings Between Jan 10, 2013, and July 17, 2017, we randomly assigned 1754 patients to receive dabigatran (n=877) or placebo (n=877); 556 patients were also randomised in the omeprazole partial factorial component. Study drug was permanently discontinued in 401 (46%) of 877 patients allocated to dabigatran and 380 (43%) of 877 patients allocated to placebo. The composite primary efficacy outcome occurred in fewer patients randomised to dabigatran than placebo (97 [11%] of 877 patients assigned to dabigatran vs 133 [15%] of 877 patients assigned to placebo; hazard ratio [HR] 0·72, 95% CI 0·55–0·93; p=0·0115). The primary safety composite outcome occurred in 29 patients (3%) randomised to dabigatran and 31 patients (4%) randomised to placebo (HR 0·92, 95% CI 0·55–1·53; p=0·76). Interpretation Among patients who had MINS, dabigatran 110 mg twice daily lowered the risk of major vascular complications, with no significant increase in major bleeding. Patients with MINS have a poor prognosis; dabigatran 110 mg twice daily has the potential to help many of the 8 million adults globally who have MINS to reduce their risk of a major vascular complication. Funding Boehringer Ingelheim and Canadian Institutes of Health Research.
- Published
- 2018
13. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
- Author
-
Devereaux, P J, primary, Duceppe, Emmanuelle, additional, Guyatt, Gordon, additional, Tandon, Vikas, additional, Rodseth, Reitze, additional, Biccard, Bruce M, additional, Xavier, Denis, additional, Szczeklik, Wojciech, additional, Meyhoff, Christian S, additional, Vincent, Jessica, additional, Franzosi, Maria Grazia, additional, Srinathan, Sadeesh K, additional, Erb, Jason, additional, Magloire, Patrick, additional, Neary, John, additional, Rao, Mangala, additional, Rahate, Prashant V, additional, Chaudhry, Navneet K, additional, Mayosi, Bongani, additional, de Nadal, Miriam, additional, Iglesias, Pilar Paniagua, additional, Berwanger, Otavio, additional, Villar, Juan Carlos, additional, Botto, Fernando, additional, Eikelboom, John W, additional, Sessler, Daniel I, additional, Kearon, Clive, additional, Pettit, Shirley, additional, Sharma, Mukul, additional, Connolly, Stuart J, additional, Bangdiwala, Shrikant I, additional, Rao-Melacini, Purnima, additional, Hoeft, Andreas, additional, Yusuf, Salim, additional, Devereaux, P.J., additional, Bangdiwala, Shrikant I., additional, Connolly, Stuart, additional, Eikelboom, John, additional, Pogue, Janice, additional, Sessler, Daniel I., additional, Di Diodato, Sara, additional, Gasic, Zora, additional, Mastrangelo, Louise J., additional, Molnar, Sarah H., additional, Swanson, Jennifer L., additional, Tosh, Makayla L., additional, Wells, Jennifer R., additional, Diaz, Rafael, additional, Chow, Clara K., additional, Gonzales, Beatriz, additional, Vásquez, Skarlet, additional, Jansky, Petr, additional, Dušek, Radovan, additional, Meyhoff, Christian S., additional, Coriat, Pierre, additional, Wittmann, Maria, additional, Yonga, Gerald, additional, Mathur, Nandini, additional, Seletti, Elena, additional, Malaga, German, additional, Tumanan-Mendoza, Bernadette A., additional, Tagle, Maria Pamela A., additional, Biccard, Bruce M., additional, Alonso-Coello, Pablo, additional, Popova, Ekaterine, additional, Shields, Martin, additional, Le Manach, Yannick, additional, Moayyedi, Paul, additional, van Zanten, Sander, additional, Fleischmann, Edith, additional, Garg, Amit, additional, Karaye, Kamilu, additional, McFalls, Edward, additional, Sigamani, Alben, additional, Belley-Côté, Emilie, additional, Biedroń, Grzegorz, additional, Borges, Flavia, additional, Frosi Stella, Steffan, additional, Haarmark Nielsen, Christian, additional, Leong, Darryl P., additional, Spence, Jessica, additional, Tran, Allen, additional, Wawrzycka-Adamczyk, Katarzyna, additional, Yang, Stephen S., additional, Yung, Terence, additional, Wyse, D. George, additional, Cheng, Davy, additional, Johnstone, David E., additional, Wells, George A., additional, Joseph, Philip, additional, Patel, Ameen, additional, Gregus, Krysten, additional, Lawrence, Kelly, additional, Doharris, Lindsay, additional, Conen, David, additional, Cheung, Jason, additional, Douketis, Jim, additional, Wright, Douglas, additional, Wikkerink, Spencer, additional, Dechert, William, additional, Panju, Mohamed, additional, Azzam, Khalid, additional, Rapanos, Theodore, additional, Van Helder, Tomas, additional, Shroff, Anjali, additional, Hare, Jacqueline, additional, Kidane, Biniam, additional, Nguyen, Thang, additional, Leydier, Larissa, additional, Bayaraa, Vanessa, additional, Parlow, Joel, additional, DuMerton, Deborah A., additional, Thakrar, Amar, additional, Shelley, Jessica, additional, Deligne, Benoit, additional, Carling, Roberta Daila, additional, Mrkobrada, Marko, additional, Dresser, George K., additional, Jacka, Michael J., additional, Hornstein, David, additional, Winkelaar, Gerrit B., additional, Haider, Zoeb Hussain, additional, Lanjewar, Pravina Prashant, additional, Varughese, Valsamma, additional, Calton, Rajneesh, additional, Ahuja, Hemani, additional, George, Preetha, additional, Sharma, Ambika, additional, Bhatt, Keyur Sureshchandra, additional, Mangukiya, Dhaval Odhavajibhai, additional, Nandaniya, Karshan Vira, additional, Parekh, Viral Vasantrai, additional, Pillai, Ashok Bhaskaran, additional, Menon, Vidya P., additional, Desai, Sanjay Channappa, additional, Sidhu, Ravinder Singh, additional, Gupta, Sandeep Kumar, additional, George, Robbie K., additional, Gurunath, T.R., additional, Drummond, Leanne W., additional, Torborg, Alexandra M., additional, Küsel, Belinda S., additional, Naidoo, Prebashini, additional, Naidoo, Datshana P., additional, Rajah, Chantal, additional, Farina, Zane, additional, von Rahden, Richard Peter, additional, Gumede, Simphiwe, additional, Chishala, Chishala, additional, Coetzee, Ettienne, additional, Dyer, Robert A., additional, Diedericks, Johan, additional, Bielański, Piotr, additional, Kaczmarek, Bogusz, additional, Studzińska, Dorota, additional, Zaniewski, Maciej, additional, Libura, Marek Józef, additional, Zacharias-Nalichowski, Tomasz Mikołaj, additional, Sega, Aurelia A.S., additional, Salwa, Jakub, additional, Kózka, Mateusz, additional, Górka, Jacek, additional, Wludarczyk, Anna, additional, Nowak-Kózka, Ilona, additional, Grudzień, Paweł Szczepan, additional, Gucwa, Jaroslaw W., additional, Słowiaczek, Michał Piotr, additional, Dobosz, Paweł P.D., additional, Gögenur, Ismail, additional, Eriksen, Jens Ravn, additional, Borup, Tine, additional, Kirkegaard, Tove, additional, Isbye, Dan, additional, Sonne, Asger, additional, Rasmussen, Lars S., additional, Pedersen, Sofie, additional, Troensegaard, Hannibal, additional, Duus, Camilla L., additional, Halle, Benedikte M., additional, Gundel, Ossian N., additional, Bernholm, Katrine F., additional, Martinsen, Kristian Rønsholt, additional, Pedersen, Søren, additional, Itenov, Theis S., additional, Camio, Elena, additional, Vázquez, Carles, additional, Matarin, Silvia, additional, Cano, Esther, additional, Álvarez-García, Jesús, additional, India, Inmaculada, additional, González-Osuna, Aránzazu, additional, Vives, Marc, additional, Rosselló, Elena, additional, Serrano, Ana B., additional, Turiel, Maurizio, additional, Drago, Lorenzo, additional, Colombo, Chiara, additional, Marra, Federica, additional, Mos, Lucio, additional, Arteni, Franco, additional, Lembo, Rosalba, additional, Ortalda, Alessandro, additional, Passarani, Simonetta, additional, Mokini, Zhirajr, additional, Figueiredo, Estevao Lanna, additional, Werner, Gustavo Fonseca, additional, Petriz, Joao Luiz, additional, Maia, Lilia Nigro, additional, Bergo, Ricardo R., additional, Precoma, Dalton Bertolim, additional, Saraiva, José Francisco Kerr, additional, Vilamajo, Oscar Gomez, additional, Allegrini, Eduardo, additional, Benzadón, Mariano, additional, Parody, Maria Leonor, additional, Duronto, Ernesto A., additional, Ingaramo, Adrián C., additional, Parra, Gustavo Adolfo, additional, Novoa, Danny, additional, Miller, Scott A., additional, Thomas, Sabu, additional, Karlapudi, Sudhakar P., additional, Bourji, Mohamad H., additional, Banerjee, Subhash, additional, Gupta, Anita, additional, Opole, Isaac O., additional, Fischer, Michal, additional, Mendoza, Victor Lecaros, additional, Reyes, Eugenio Borja, additional, Pierson, Richard J., additional, Shields, Martin O., additional, Piriou, Vincent, additional, Zacharowski, Kai, additional, Rotta-Rotta, Aida, additional, Paper, Main, additional, Srinathan, Sadeesh K., additional, Rahate, Prashant, additional, Chaudhry, Navneet, additional, Mayosi, Bogani, additional, Paniagua Iglesias, Pilar, additional, and Sharma, Mike, additional
- Published
- 2018
- Full Text
- View/download PDF
14. The prevalence, determinants, natural history and impact of atrial fibrillation and atrial flutter in patients with tuberculosis pericarditis - insights from the IMPI trial
- Author
-
Chishala, Chishala, Pandie, Shaheen, Gumedze, Freedom, and Mayosi, Bongani M
- Subjects
Cardiology - Abstract
Tuberculosis is the most common cause of pericarditis in Africa. The dual human immunodeficiency virus (HIV)-tuberculosis epidemics are major contributors to the burden of extra-pulmonary tuberculosis, including tuberculous pericarditis. Mortality rates remain unacceptably high. Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice. It is associated with increased cardiovascular mortality and morbidity, as well as complications related to thromboembolic disease and haemodynamic instability. Similarly, atrial flutter (AFL) is a common macro-reentry arrhythmia, often associated with AF and its complications. While there is a recognized association between atrial fibrillation and / or atrial flutter (AF/AFL) and tuberculous pericarditis, there are limited data regarding the prevalence, determinants, natural history, and outcomes of AF/AFL in tuberculous pericarditis. Hypothesis: In patients with tuberculous pericarditis, AF/AFL is common, and when compared to tuberculous pericarditis patients that are in sinus rhythm, is associated with increased morbidity and mortality. Aims In participants with tuberculous pericarditis enrolled into the Investigation of the Management of Pericarditis (IMPI) trial, we intend to: 1. Estimate the prevalence of AF/AFL 2. Describe the natural history of AF/AFL 3. Identify clinical, biochemical and, echocardiographic predictors of AF/AFL 4. Determine the clinical impact of AF/AFL.
- Published
- 2016
15. Acute coronary syndrome due to coronary vasospasm associated with thyrotoxicosis.
- Author
-
Chishala, Chishala
- Subjects
- *
ISCHEMIA , *CHEST pain , *HYPERTHYROIDISM , *MYOCARDIAL infarction , *THYROID gland function tests - Abstract
The article describes the case of a 37 year old mother presented with 1-day history of severe ischaemic type chest pain occurring at rest and associated autonomic symptoms of nausea, vomiting and excessive sweating. She was assessed to have thyrotoxicosis with non-ST-segment elevation myocardial infarction (NSTEMI) and was treated with an infusion of unfractionated heparin, aspirin and simvastatin. It suggests thyroid function tests for patients presenting with chest pain due to coronary spasm.
- Published
- 2012
16. Rationale, Design, and the Baseline Characteristics of the RHDGen (The Genetics of Rheumatic Heart Disease) Network Study†.
- Author
-
Machipisa T, Chishala C, Shaboodien G, Zühlke LJ, Muhamed B, Pandie S, de Vries J, Laing N, Joachim A, Daniels R, Ntsekhe M, Hugo-Hamman CT, Gitura B, Ogendo S, Lwabi P, Okello E, Damasceno A, Novela C, Mocumbi AO, Madeira G, Musuku J, Mtaja A, ElSayed A, Alhassan HHM, Bode-Thomas F, Yilgwan C, Amusa G, Nkereuwem E, Mulder N, Ramesar R, Lesosky M, Cordell HJ, Chong M, Keavney B, Paré G, and Engel ME
- Subjects
- Humans, Female, Adolescent, Genome-Wide Association Study, Echocardiography, Rheumatic Heart Disease genetics, Rheumatic Fever, Atrial Fibrillation
- Abstract
Background: The genetics of rheumatic heart disease (RHDGen) Network was developed to assist the discovery and validation of genetic variations and biomarkers of risk for rheumatic heart disease (RHD) in continental Africans, as a part of the global fight to control and eradicate rheumatic fever/RHD. Thus, we describe the rationale and design of the RHDGen study, comprising participants from 8 African countries., Methods: RHDGen screened potential participants using echocardiography, thereafter enrolling RHD cases and ethnically-matched controls for whom case characteristics were documented. Biological samples were collected for conducting genetic analyses, including a discovery case-control genome-wide association study (GWAS) and a replication trio family study. Additional biological samples were also collected, and processed, for the measurement of biomarker analytes and the biomarker analyses are underway., Results: Participants were enrolled into RHDGen between December 2012 and March 2018. For GWAS, 2548 RHD cases and 2261 controls (3301 women [69%]; mean age [SD], 37 [16.3] years) were available. RHD cases were predominantly Black (66%), Admixed (24%), and other ethnicities (10%). Among RHD cases, 34% were asymptomatic, 26% had prior valve surgery, and 23% had atrial fibrillation. The trio family replication arm included 116 RHD trio probands and 232 parents., Conclusions: RHDGen presents a rare opportunity to identify relevant patterns of genetic factors and biomarkers in Africans that may be associated with differential RHD risk. Furthermore, the RHDGen Network provides a platform for further work on fully elucidating the causes and mechanisms associated with RHD susceptibility and development.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.